MedPath

Lamivudine

Generic Name
Lamivudine
Brand Names
Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
Drug Type
Small Molecule
Chemical Formula
C8H11N3O3S
CAS Number
134678-17-4
Unique Ingredient Identifier
2T8Q726O95
Background

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication

For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions
Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

Completed
Conditions
Lactating Women on Select DOI
Breastmilk Fed Infants of Mothers on Select DOI
HIV Infections
Interventions
First Posted Date
2021-04-28
Last Posted Date
2025-02-06
Lead Sponsor
Duke University
Target Recruit Count
164
Registration Number
NCT04862975
Locations
🇿🇦

Botswana-UPenn Partnership, Botswana, Gaborone, South Africa

🇿🇦

Lesirane Clinic, Botswana, Gaborone, South Africa

🇿🇦

Mogoditshane Clinic KDC, Botswana, Gaborone, South Africa

and more 1 locations

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

Phase 2
Completed
Conditions
Aicardi-Goutières Syndrome
Interventions
First Posted Date
2021-01-29
Last Posted Date
2024-05-09
Lead Sponsor
University of Edinburgh
Target Recruit Count
13
Registration Number
NCT04731103
Locations
🇬🇧

Yanick Crow, Edinburgh, United Kingdom

Reducing Vertical Transmission of Hepatitis B in Africa

Phase 3
Recruiting
Conditions
Hepatitis B Infection
Interventions
First Posted Date
2021-01-11
Last Posted Date
2024-10-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
450
Registration Number
NCT04704024
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
First Posted Date
2021-01-06
Last Posted Date
2025-05-15
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
28
Registration Number
NCT04696575
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

REal-Life Cohort With DOlutegravir + LAmivudina

Completed
Conditions
HIV-1-infection
First Posted Date
2020-11-20
Last Posted Date
2023-11-14
Lead Sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Target Recruit Count
185
Registration Number
NCT04638686
Locations
🇪🇸

Alfonso Cabello, Madrid, Spain

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer Disease, Early Onset
Interventions
First Posted Date
2020-09-17
Last Posted Date
2024-08-09
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
12
Registration Number
NCT04552795
Locations
🇺🇸

Sam and Ann Barshop Institute for Longevity & Aging Studies, San Antonio, Texas, United States

🇺🇸

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States

🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

Phase 4
Completed
Conditions
Hiv
HIV-1-infection
Interventions
First Posted Date
2020-09-16
Last Posted Date
2024-02-21
Lead Sponsor
Fundacion IDEAA
Target Recruit Count
244
Registration Number
NCT04549467
Locations
🇦🇷

Fundacion IDEAA, Buenos Aires, Argentina

Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

Phase 3
Conditions
HIV-infection/Aids
Interventions
Drug: EFV
Drug: FNC placebo
First Posted Date
2020-03-11
Last Posted Date
2020-03-11
Lead Sponsor
HeNan Sincere Biotech Co., Ltd
Target Recruit Count
720
Registration Number
NCT04303598
Locations
🇨🇳

Beijing DiTan Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Chongqing Public Health Medical Center, Chongqing, Chongqing, China

and more 9 locations

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Early Phase 1
Completed
Conditions
Medication Adherence
HIV
Interventions
Drug: emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg
First Posted Date
2020-03-10
Last Posted Date
2022-03-03
Lead Sponsor
Rhonda Brand
Target Recruit Count
30
Registration Number
NCT04302896
Locations
🇺🇸

HIV/AIDS Clinical Research Unit / University of Pittsburgh, Pittsburgh, Pennsylvania, United States

ANRS 12372 MODERATO Study

First Posted Date
2019-07-17
Last Posted Date
2023-09-06
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
480
Registration Number
NCT04022967
Locations
🇨🇮

Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Côte D'Ivoire

🇧🇫

Service de médecine interne, CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso

🇧🇫

Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy